BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sidamo T, Shibeshi W, Yimer G, Aklillu E, Engidawork E. Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study. Infect Drug Resist 2021;14:5473-89. [PMID: 34984005 DOI: 10.2147/IDR.S342964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu J, Xu Y, Li Z, Chen X, Lin H, Zhao Q. Diagnosis and Treatment Pathway of MDR/RR-TB in Taizhou, Zhejiang Province, China. Trop Med Infect Dis 2023;8. [PMID: 36828495 DOI: 10.3390/tropicalmed8020079] [Reference Citation Analysis]
2 Sidamo T, Rao PS, Aklillu E, Shibeshi W, Park Y, Cho Y, Shin J, Heysell SK, Mpagama SG, Engidawork E. Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis. IDR 2022;Volume 15:6839-6852. [DOI: 10.2147/idr.s389442] [Reference Citation Analysis]
3 Baluku JB, Ronald O, Bagasha P, Okello E, Bongomin F. Prevalence of cardiovascular risk factors in active tuberculosis in Africa: a systematic review and meta-analysis. Sci Rep 2022;12:16354. [PMID: 36175540 DOI: 10.1038/s41598-022-20833-0] [Reference Citation Analysis]
4 Onakpoya IJ. Drugs used in the treatment of tuberculosis and leprosy. Side Effects of Drugs Annual 2022. [DOI: 10.1016/bs.seda.2022.08.011] [Reference Citation Analysis]